Whalesbook
Prism Medico Faces Scrutiny Amidst Revenue Plunge and Accounting Anomaly
Prism Medico And Pharmacy Limited is under the spotlight after announcing its unaudited standalone financial results for the quarter ended December 31, 2025 (Q3 FY26). The numbers paint a concerning picture, marked by a dramatic fall in operational revenue and a significant accounting discrepancy that has raised serious questions about financial reporting integrity.
Financial Deep Dive
The Numbers: The company reported a stark 85.86% year-on-year (YoY) decline in revenue from operations, which slumped to ₹7.10 Cr in Q3 FY26 from ₹50.23 Cr in the same period last year. Sequentially, revenue also dropped 65.96% from ₹20.86 Cr in the previous quarter. Adding to the concerns, Prism Medico reported 'Total income from operations' at ₹71.79 Cr for Q3 FY26. However, this figure is inconsistent and does not add up when combined with 'Revenue from operations' (₹7.10 Cr) and 'Other income' (₹0.69 Cr), which total only ₹7.79 Cr. This represents a significant accounting anomaly, a major red flag for investors.
While the company reported a Net Loss of ₹1.34 Cr for Q3 FY26, this is an improvement in absolute terms from the Net Loss of ₹8.48 Cr in Q3 FY25. However, it marks a worsening loss compared to the ₹0.96 Cr net loss reported in the immediately preceding quarter (Q4 FY25). Basic and Diluted EPS stood at a negligible ₹(0.0002). Despite the quarterly setback, the company achieved a Net Profit of ₹55.91 Cr for the nine months ended December 31, 2025 (9M FY26), a significant turnaround from a Net Loss of ₹4.87 Cr during the same period in FY25.
Expenses: The cost of materials consumed also saw a substantial YoY decline, mirroring the reduced operational scale. However, the reconciliation issue with total income remains the paramount concern.
The Grill
Analysts are certain to grill management on two critical points: the dramatic 85.86% YoY fall in 'Revenue from operations' and, more importantly, the significant accounting anomaly where 'Total income from operations' (₹71.79 Cr) does not reconcile with the sum of its components (₹7.79 Cr). The disconnect raises fundamental questions about the accuracy of Prism Medico's financial reporting and the underlying operational health. Investors will demand a clear, detailed explanation for both the revenue collapse and the discrepancy in the income statement.
Risks & Outlook
Operational Performance: The 85.86% YoY decline in revenue from operations is a severe indicator of distress or a fundamental shift in the company's business. Investors will need clarity on the reasons behind this drastic drop.
Financial Anomaly: The most pressing issue is the discrepancy in Q3 FY26's financial reporting. The 'Total income from operations' figure of ₹71.79 Cr is inconsistent with the sum of its reported components (₹7.79 Cr). This anomaly not only suggests potential errors in accounting but also raises questions about the accuracy and reliability of the company's financial statements. Such issues can lead to regulatory scrutiny and damage investor confidence.
The Forward View: Investors will be keenly watching for explanations regarding the revenue collapse and, critically, the accounting anomaly. The company's ability to provide a clear, reconcilable financial picture and a credible plan to reverse the operational revenue decline will be key determinants of future investor sentiment. Any further regulatory investigation or lack of clarity could lead to sustained pressure on the stock.